New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control
Completed
This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC